Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(0.73)
# 3,804
Out of 4,396 analysts
121
Total ratings
37%
Success rate
-3.5%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $4 | $2.12 | +88.68% | 1 | May 21, 2026 | |
| IKT Inhibikase Therapeutics | Maintained: Buy | $4 | $1.67 | +139.52% | 2 | May 18, 2026 | |
| PTHS Pelthos Therapeutics | Initiated Coverage: Buy | $50 | $26.90 | +85.87% | 1 | Apr 1, 2026 | |
| CTMX CytomX Therapeutics | Maintained: Buy | $10 → $12 | $2.98 | +302.68% | 5 | Mar 20, 2026 | |
| GOSS Gossamer Bio | Downgraded: Hold | n/a | $0.16 | - | 6 | Mar 20, 2026 | |
| TENX Tenax Therapeutics | Initiated Coverage: Buy | $35 | $10.73 | +226.19% | 1 | Mar 17, 2026 | |
| UTHR United Therapeutics | Initiated Coverage: Buy | $525 → $625 | $553.14 | +12.99% | 4 | Mar 12, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $85 | $57.91 | +46.78% | 18 | Mar 2, 2026 | |
| VNDA Vanda Pharmaceuticals | Maintained: Buy | $11 | $6.12 | +79.74% | 5 | Feb 23, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Hold | $450 → $400 | $297.69 | +34.37% | 11 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $192 → $230 | $99.04 | +132.23% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $3.57 | n/a | 4 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $480 | $445.77 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $405 → $340 | $344.57 | n/a | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $52 → $55 | $56.48 | n/a | 8 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $70 → $80 | $125.50 | n/a | 8 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $795 → $925 | $616.18 | n/a | 4 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $10 | $15.78 | n/a | 6 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $9.97 | n/a | 1 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $51.48 | n/a | 3 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 | $6.79 | n/a | 4 | Mar 20, 2023 |
Connect Biopharma Holdings
May 21, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $2.12
Upside: +88.68%
Inhibikase Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $4
Current: $1.67
Upside: +139.52%
Pelthos Therapeutics
Apr 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $26.90
Upside: +85.87%
CytomX Therapeutics
Mar 20, 2026
Maintained: Buy
Price Target: $10 → $12
Current: $2.98
Upside: +302.68%
Gossamer Bio
Mar 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.16
Upside: -
Tenax Therapeutics
Mar 17, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $10.73
Upside: +226.19%
United Therapeutics
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $525 → $625
Current: $553.14
Upside: +12.99%
BioMarin Pharmaceutical
Mar 2, 2026
Maintained: Buy
Price Target: $85
Current: $57.91
Upside: +46.78%
Vanda Pharmaceuticals
Feb 23, 2026
Maintained: Buy
Price Target: $11
Current: $6.12
Upside: +79.74%
Alnylam Pharmaceuticals
Feb 12, 2026
Maintained: Hold
Price Target: $450 → $400
Current: $297.69
Upside: +34.37%
Dec 16, 2025
Maintained: Buy
Price Target: $192 → $230
Current: $99.04
Upside: +132.23%
Mar 20, 2025
Maintained: Buy
Price Target: $9
Current: $3.57
Upside: n/a
Feb 11, 2025
Reiterated: Buy
Price Target: $480
Current: $445.77
Upside: n/a
Feb 5, 2025
Maintained: Buy
Price Target: $405 → $340
Current: $344.57
Upside: n/a
Feb 4, 2025
Maintained: Hold
Price Target: $52 → $55
Current: $56.48
Upside: n/a
Nov 6, 2024
Maintained: Hold
Price Target: $70 → $80
Current: $125.50
Upside: n/a
Apr 17, 2024
Maintained: Hold
Price Target: $795 → $925
Current: $616.18
Upside: n/a
Feb 23, 2024
Maintained: Buy
Price Target: $15 → $10
Current: $15.78
Upside: n/a
Nov 10, 2023
Downgraded: Hold
Price Target: n/a
Current: $9.97
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $51.48
Upside: n/a
Mar 20, 2023
Maintained: Hold
Price Target: $3
Current: $6.79
Upside: n/a